© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The process toward a creating a healthier lifestyle and discovering my genotype.
A majority of people taking antiretrovirals to treat HIV could switch to newer regimens with improved side effect profiles.
Global prices for first- and second-line HIV therapies have plummeted, but newer therapies are still hugely expensive.
The U.S. Food and Drug Administration has approved changes to the labels for the antiretrovirals (ARVs) Intelence (etravirine) and Prezista (d...
Children between 6 and 17 years old may now use Intelence, a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has shown to be...
A drug regimen containing Isentress (raltegravir), Intelence (etravirine) and Norvir (ritonavir)–boosted Prezista (darunavir)...
If you have lived with HIV for a long time and have exhausted various med combos in the past, there are still options.
Companies that develop HIV drugs are at a standstill in bringing new medicines to market, Bloomberg reports.
A drug regimen containing Isentress (raltegravir), Intelence (etravirine) and Norvir (ritonavir)?boosted Prezista (darunavir) continues to wor...
Good news for Intelence (etravirine) users: Instead of two 100 milligram (mg) tablets twice a day, the recent approval of a 200 mg tablet will...
People on a regimen containing efavirenz (found in Sustiva and Atripla) who have neurological side effects or abnormal cholesterol or triglyce...
Johnson & Johnson plans to expand its work in infectious diseases such as HIV, hepatitis C and the flu.
People with central nervous system (CNS) side effects, who switched from Sustiva (efavirenz) plus two nucleoside reverse transcriptase inhibit...
People whose HIV levels drop more slowly after starting antiretroviral (ARV) therapy do just as well over two years as people whose virus drop...
HIV drug news
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.